Survodutide: The GLP-1/Glucagon Dual-Agonist Evidence Reviewed (2026)
By Theo Park · Editor, Privacy & Safety
Updated Jun 2026Survodutide is an injectable drug that hits two gut-hormone receptors at once: the GLP-1 receptor that powers drugs like semaglutide, plus the glucagon receptor that older weight-loss drugs left alone. Made by Boehringer Ingelheim and still known by its lab code BI 456906, it has moved through Phase 2 trials in obesity and liver disease and posted its first Phase 3 results in 2026. This review walks through what the human data actually show, where the evidence is strong, and where it is still thin.
Survodutide is an injectable drug that hits two gut-hormone receptors at once: the GLP-1 receptor that powers drugs like semaglutide, plus the glucagon receptor that older weight-loss drugs left alone. Made by Boehringer Ingelheim and still known by its lab code BI 456906, it has moved through Phase 2 trials in obesity and liver disease and posted its first Phase 3 results in 2026. This review walks through what the human data actually show, where the evidence is strong, and where it is still thin.
What Survodutide Is
Survodutide is a peptide-based dual agonist. "Agonist" means it switches a receptor on. The two receptors it targets are:
- GLP-1 receptor — the same target as semaglutide (Wegovy, Ozempic). Turning it on slows stomach emptying, cuts appetite, and improves blood sugar control.
- Glucagon receptor — glucagon is best known for raising blood sugar, but it also speeds up how fast the body burns energy and pushes the liver to break down stored fat.
The idea is that combining the two does more than either alone. GLP-1 handles appetite and blood sugar. Glucagon adds an energy-burn and direct liver effect on top. That second lever is what sets survodutide apart from GLP-1-only drugs and from the GLP-1/GIP combo in tirzepatide.
It is given as a once-weekly shot under the skin. Like other drugs in this class, the dose is raised slowly over weeks. This "titration" matters more for survodutide than for most GLP-1 drugs, because the glucagon side adds its own stomach upset on top of the usual GLP-1 nausea. Trials started people low — often 0.6 mg — and stepped up over a couple of months toward the target dose. Rush the climb and people quit; go too slow and they wait longer for the benefit. Getting that schedule right is part of why the drug has taken years to develop.
One thing to be clear about up front: as of mid-2026, survodutide is not approved by the FDA or any major regulator. Every result below comes from clinical trials, not from real-world use of an approved medicine. That said, regulators are paying attention. The FDA granted survodutide Breakthrough Therapy designation in 2024 for non-cirrhotic MASH with moderate-to-advanced fibrosis (stages F2-F3), and the European Medicines Agency accepted it into its PRIME scheme back in 2023. Both labels speed up review for promising drugs; neither one means the drug works or is safe enough to sell. The Phase 3 obesity and liver programs that read out in 2026 are the data a regulator would actually weigh for approval.
How it compares to the rest of the class
The incretin drug field has climbed a ladder of complexity. Here is where survodutide sits.
| Drug | Receptors hit | Status (mid-2026) | Peak weight loss in trials |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA approved | ~15% |
| Tirzepatide | GLP-1 + GIP | FDA approved | ~21-22% |
| Survodutide | GLP-1 + glucagon | Phase 3, not approved | ~16-19% |
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3, not approved | ~24-28% |
Notice that survodutide is the only one here that adds glucagon without GIP. That makes it a distinct experiment, not just a stronger version of an existing drug. The glucagon arm is the bet, and the liver data are where it shows up most clearly.
The Mechanism: Why Add Glucagon?
GLP-1-only drugs work mainly by making you eat less. They are very good at that. But appetite suppression alone has limits, and it does not directly tell the liver to burn its own fat.
Glucagon receptor activation adds two things in theory:
- Higher energy expenditure. Glucagon can nudge the body to burn more calories at rest, which means weight comes off through more than just eating less.
- Direct liver fat clearance. The glucagon receptor sits on liver cells. Switching it on pushes the liver to break down stored fat (lipolysis) and burn it. This is why survodutide has been studied so heavily in fatty liver disease, not just obesity.
There is a catch, and the research community has flagged it honestly: glucagon raises blood sugar. On its own, that would be a problem for people with or near diabetes. The design bet is that the GLP-1 side of the molecule keeps blood sugar in check while the glucagon side does its metabolic work. Phase 2 data suggest the balance holds, but this remains the central open question for the whole glucagon-agonist approach. It is a real engineering tradeoff, not a solved problem.
The balance also depends on how strongly the molecule pulls on each receptor. Survodutide is not a 50/50 split — it is tuned to favor a specific ratio of glucagon to GLP-1 activity, and that ratio is part of what the company is trying to get right. Push the glucagon side too hard and you risk blood-sugar problems and a faster heart rate; lean too far toward GLP-1 and you lose the extra fat-burning that justifies the whole approach. The fact that the 4.8 mg dose, not the highest 6.0 mg dose, often performed best in trials hints that there is a sweet spot rather than a "more is better" curve. That is a meaningful clue for anyone trying to read where the approved dose, if it comes, might land.
If you want the broader picture of how appetite hormones drive these drugs, the semaglutide mechanism of action review covers the GLP-1 side in depth.
The Evidence on Weight Loss
This is the strongest, most repeated part of the survodutide story, and it now spans both Phase 2 and Phase 3.
Phase 2 obesity trial (2024)
The dose-finding Phase 2 trial was published in The Lancet Diabetes & Endocrinology in March 2024. It enrolled adults with overweight or obesity but without type 2 diabetes, and tested four doses against placebo over 46 weeks.
The headline result: people who completed treatment at the top 4.8 mg dose lost close to 19% of their body weight. The more conservative analysis that counts everyone assigned to that dose (including those who stopped early) showed roughly 15%. Placebo was around 2-3%. About 40% of people on the highest dose lost at least 20% of their weight.
That is a strong Phase 2 signal. It put survodutide in the same conversation as tirzepatide and well ahead of older GLP-1-only drugs.
Phase 3 SYNCHRONIZE-1 (2026)
The Phase 3 program is called SYNCHRONIZE. Topline results from SYNCHRONIZE-1, the main obesity trial, were reported in 2026 and presented at the American Diabetes Association's 2026 Scientific Sessions. It ran 76 weeks in adults with obesity or overweight and no type 2 diabetes.
| Measure | Survodutide (top dose) | Placebo |
|---|---|---|
| Average weight loss (efficacy estimand) | ~16.6% | ~3.2% |
| Average weight loss (treatment-regimen estimand) | ~12-13% | ~5% |
| Reached at least 5% weight loss | up to ~85% | much lower |
| Visceral (belly) fat reduction | up to ~34% | — |
| Liver fat reduction | up to ~63% | — |
A few honest notes on these numbers. First, the gap between the two "estimands" matters. The ~16.6% figure is the efficacy estimand — roughly, weight loss in people who stayed on the drug as intended. The treatment-regimen estimand, which counts everyone regardless of whether they stopped, lands lower at around 12-13%. Both are valid ways to read a trial; the lower number is closer to what an average patient might expect because it bakes in dropouts.
Second, the body-composition data are a genuine strength. Cutting visceral fat by a third and liver fat by nearly two-thirds, while losing relatively little lean (muscle) mass, fits the mechanism story: the glucagon arm is doing metabolic work, not just shrinking appetite.
Third — and this is the sober part — a Phase 3 weight loss of ~16.6% lands survodutide ahead of semaglutide but behind tirzepatide's ~21-22% and well behind retatrutide's ~24-28% in their own trials. Survodutide is not the most powerful drug in the pipeline on the scale. Cross-trial comparisons like this are rough — different patients, different protocols — but the rank order has held up across analyses. There is no published head-to-head trial pitting survodutide directly against tirzepatide or retatrutide, so any "X beats Y" claim is an inference, not a proven fact.
For how the triple agonist stacks up, the tirzepatide vs retatrutide comparison and the retatrutide triple agonist Phase 2 results lay out that side of the field.
The Evidence on Liver Disease (MASH/MASLD)
This is where survodutide's glucagon angle may matter most, and the data are arguably more interesting than the weight numbers.
Phase 2 MASH trial (2024)
Published in The New England Journal of Medicine in 2024, this trial enrolled 293 adults with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis, the more serious form of fatty liver disease) and fibrosis stages F1 to F3. People got survodutide at 2.4, 4.8, or 6.0 mg, or placebo, once weekly for 48 weeks.
The primary endpoint was improvement in MASH without worsening of liver scarring (fibrosis). The results:
| Group | MASH improved, no worse fibrosis |
|---|---|
| Survodutide 2.4 mg | 47% |
| Survodutide 4.8 mg | 62% |
| Survodutide 6.0 mg | 43% |
| Placebo | 14% |
Every survodutide dose beat placebo by a wide margin. Notably, the 4.8 mg dose did best, and the highest 6.0 mg dose did not add benefit — a reminder that more is not always better. The trial also showed improvement in fibrosis itself in a meaningful share of patients, which is the harder, more important goal in liver disease.
Phase 3 SYNCHRONIZE-MASLD (2026)
A Phase 3 liver trial, SYNCHRONIZE-MASLD, was published in Nature Medicine in 2026. It studied people with fatty liver disease plus obesity or overweight over 48 weeks and hit both primary endpoints. Reported results included roughly 6 in 10 participants reaching normal liver fat, and up to ~84% achieving at least a 30% relative cut in liver fat versus ~24% on placebo.
The liver story is the part of the survodutide case that is hardest to dismiss. The mechanism predicts a direct liver effect, and both a Phase 2 biopsy trial and a Phase 3 imaging trial delivered one. That said, "improvement in liver fat and MASH activity" is not the same as proving long-term outcomes like preventing cirrhosis or liver failure — those take longer trials that have not finished.
Other Findings and Open Questions
Blood pressure. A 2025 post hoc analysis of the Phase 2 obesity trial found survodutide also lowered blood pressure. Useful, but "post hoc" means the analysis was done after the fact rather than planned in advance, so it is a supporting signal, not proof.
Blood sugar. Because glucagon can raise glucose, the diabetes data are watched closely. So far the GLP-1 side appears to keep things balanced, but a dedicated, fully reported Phase 3 program in type 2 diabetes is what would settle it.
Durability. The Phase 3 obesity trial ran 76 weeks. Whether weight stays off long-term, and what happens after stopping, are unanswered — the same open question that applies to the whole class. With GLP-1 drugs, much of the lost weight tends to come back after people stop, and there is no reason yet to think survodutide is different.
Hard liver outcomes. A separate Phase 3 liver trial called LIVERAGE is designed to run for years and ask the question that really matters in MASH: does the drug cut the risk of end-stage liver disease, not just improve a biopsy or a scan? Those results are not in. Until they are, the liver case rests on shorter "surrogate" endpoints — real signals, but not the final word.
What to watch next
For anyone tracking survodutide, the milestones that will decide its fate are clear:
- Full Phase 3 obesity data. Topline numbers landed in 2026, but the complete peer-reviewed dataset — including how durable the weight loss is and the full safety breakdown by dose — is what tells the real story.
- A regulatory filing. No submission means no approval. Watch for Boehringer to file with the FDA and EMA, and for the indication they choose first: obesity, MASH, or both.
- Long-term liver outcomes (LIVERAGE). The multi-year trial that could move survodutide from "improves liver markers" to "prevents liver failure."
- Any head-to-head trial. So far every comparison to tirzepatide or retatrutide is indirect. A direct trial would settle the ranking — and none has been reported.
None of these are guaranteed. Promising Phase 2 and Phase 3 drugs still fail or stall in review. The honest stance is cautious interest, not a foregone conclusion.
Safety and Tolerability
The side effect profile is the clearest weak spot, and it deserves a straight look.
Like all drugs in this class, survodutide's main problems are gastrointestinal: nausea, vomiting, and diarrhea, mostly during the dose-escalation phase. In the Phase 2 MASH trial, rates were high compared with placebo:
| Side effect | Survodutide | Placebo |
|---|---|---|
| Nausea | 66% | 23% |
| Diarrhea | 49% | 23% |
| Vomiting | 41% | 4% |
| Serious adverse events | 8% | 7% |
The serious-event rates were similar to placebo, which is reassuring. But the everyday GI burden is heavy. The bigger concern showed up in Phase 3: in SYNCHRONIZE-1, GI side effects led to stopping the drug in roughly 18% of people on the 3.6 mg dose and about 20% on the 6.0 mg dose, versus under 3% on placebo. Boehringer has called tolerability "consistent with the class," but those discontinuation numbers are on the higher end, and some industry analysts have flagged them as a real question mark for a drug whose weight-loss edge over tirzepatide is not obvious.
In plain terms: a meaningful share of people in the trials could not stay on the higher doses because they felt too sick. That matters because the biggest weight loss came from those higher doses.
For how this class compares to hormone therapy on the safety front, see peptide therapy vs TRT.
Who Survodutide Is Being Developed For
Based on the trial programs, the target groups are:
- Adults with obesity or overweight (with a weight-related health problem), without type 2 diabetes — the SYNCHRONIZE-1 population.
- People with MASH or MASLD, the metabolic fatty liver diseases — where the glucagon-driven liver effect is the main selling point.
Who it is not for, today: anyone. It is not approved, not prescribable for general use, and only available inside clinical trials. Products sold online as "survodutide" from research-chemical or gray-market vendors are not the regulated drug, have not been tested for purity or dose accuracy, and carry real safety risk. The honest answer to "can I get survodutide in 2026?" is: only by enrolling in a trial.
If you are weighing approved options now, the broader GLP-1 mechanism review and the tirzepatide vs retatrutide comparison cover drugs you can actually be prescribed.
Evidence Grade: An Honest Summary
| Claim | Strength of evidence |
|---|---|
| Causes meaningful weight loss | Strong — Phase 2 and Phase 3, hundreds of patients |
| Improves MASH and liver fat | Strong — biopsy Phase 2 plus imaging Phase 3 |
| Beats semaglutide on weight | Moderate — cross-trial, no head-to-head |
| Beats tirzepatide on weight | Weak/unlikely — appears lower, no head-to-head |
| Safe long-term | Unproven — longest data ~76 weeks |
| Manageable side effects | Mixed — serious events low, but high GI dropout |
| Holds blood sugar steady despite glucagon | Promising but unsettled |
The short version: the weight and liver data are real and repeated across trial phases, which is more than most pipeline peptides can say. The weak spots are tolerability at effective doses, the lack of any direct comparison to the drugs already on pharmacy shelves, and the simple fact that it is not yet approved.
Frequently Asked Questions
Is survodutide FDA approved?
No. As of mid-2026, survodutide is investigational. It has completed Phase 2 trials and reported Phase 3 results in obesity and fatty liver disease, but Boehringer Ingelheim has not received marketing approval from the FDA or other major regulators. It can only be accessed through clinical trials.
How much weight do people lose on survodutide?
In the Phase 2 obesity trial, people who completed the top dose lost close to 19% of their body weight over 46 weeks. In the Phase 3 SYNCHRONIZE-1 trial, average loss was about 16.6% over 76 weeks by the efficacy estimand, or roughly 12-13% by the more conservative analysis that counts everyone enrolled. Placebo was around 3%.
How is survodutide different from semaglutide and tirzepatide?
Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 and GIP). Survodutide also hits two, but a different pair: GLP-1 and glucagon. The glucagon arm is meant to add energy burn and a direct liver-fat effect, which is why survodutide has been studied so heavily in fatty liver disease.
Does survodutide help with fatty liver disease?
The trial data say yes. In a Phase 2 biopsy trial, up to 62% of patients saw MASH improve without worsening fibrosis, versus 14% on placebo. A Phase 3 imaging trial showed most participants reaching normal liver fat. These are strong short-term liver signals, though long-term outcomes like preventing cirrhosis have not been proven.
What are the side effects of survodutide?
Mostly gastrointestinal: nausea, vomiting, and diarrhea, especially while the dose is being raised. Rates were high in trials (nausea around 66% in the MASH study), and in Phase 3 about 18-20% of people on higher doses stopped the drug because of GI side effects. Serious adverse events were similar to placebo.
The Bottom Line
Survodutide is one of the more credible next-generation obesity and liver drugs in development, backed by repeated Phase 2 and Phase 3 data rather than hype. Its glucagon angle gives it a standout liver-fat profile. But it lands behind tirzepatide and retatrutide on raw weight loss, carries a heavy GI side effect burden at effective doses, has never been compared head-to-head with approved drugs, and is not available outside trials. Watch the regulatory filings — not the gray market.
This article is for educational purposes only and is not medical advice. Survodutide is investigational and not approved for use. Talk to a licensed physician before making any treatment decision.
Sources
- Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024.
- Le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024.
- Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026.
- Survodutide for treatment of obesity: Baseline characteristics in the phase 3 SYNCHRONIZE-1 trial. Diabetes Obes Metab. 2026.
- Survodutide improves blood pressure in adults with obesity: a post hoc analysis of a phase 2 trial. Diabetes Obes Metab. 2025.
- ClinicalTrials.gov. SYNCHRONIZE-1 obesity study record (NCT06066515).
- PubMed: survodutide obesity trials (literature search).
- PubMed: all survodutide publications (literature search).
On Google
Get our answers in your Google results.
Add Peptide Front as a preferred source and Google will surface our peptide research more often — in Top Stories and AI answers, marked with a preferred badge. One tap, free, undo anytime.
Add us as a preferred sourceOpens Google's source preferences for peptidefront.com. No sign-up with us — it's a Google setting.